Navigation Links
U-M sibling study discovers genetic region linked to control of key blood-clotting protein
Date:1/8/2013

ANN ARBORIn 2006, the lab of Dr. David Ginsburg at the Life Sciences Institute put a call out for siblings attending the University of Michigan to donate blood for a study of blood-clotting disorders.

The samples were collected over three years and have now enabled the researchers to identify the specific parts of the genome responsible for levels of a key substance for blood clotting. The findings were reported online Dec. 24 in the Proceedings of the National Academy of Sciences.

Von Willebrand disease is the most common hereditary blood-clotting disorderit's more common, but usually milder, than hemophilia. The disease is caused by lower-than-normal levels of von Willebrand factor, a substance that circulates in blood and serves as the "glue" to help blood platelets stick where they're needed to stop bleeding.

While a low level of von Willebrand factor may cause uncontrolled bleeding, high levels can contribute to blood clots, heart attacks and strokes. Age and environmental factors can lead to increased von Willebrand factor, and understanding how the body regulates the substance can help researchers develop treatments for diseases caused by excessive clotting.

Previous studies pinpointed two major genes that partially regulated levels of von Willebrand factor in the blood. However, these two genes only explained a small part of the inherited differences in von Willebrand factor levels between people. Studying siblings in college provided some clues to those differences.

A team of researchers led by Ginsburg, who is a faculty member at the Life Sciences Institute, a professor of internal medicine, human genetics and pediatrics at the U-M Medical School and a Howard Hughes Medical Institute investigator, performed a genetic analysis in two young and healthy cohorts. Because the blood donors were in their early 20s, the effect of other factors known to cause an excess of von Willebrand factor, like age and smoking, were minimized, giving the scientists a better chance of uncovering genetic causes.

The researchers report that the first part of their analysis, called a genome-wide association study, confirmed the two major genes already known to explain a small part of the differences in von Willebrand factor.

The researchers also looked at which parts of the genome were shared between siblings and how this related to von Willebrand factor levels. They identified a section of chromosome 2 that contains a gene that significantly regulates von Willebrand factor but had not previously been detected in studies of unrelated individuals.

The next step will be to determine the identity of the exact gene on chromosome 2, how it differs among people, and how these differences alter the level of von Willebrand factor and the associated risk for bleeding and blood clotting. Understanding how this gene affects von Willebrand factor may lead to improved diagnosis for bleeding and blood-clotting disorders, as well as new approaches to treatment.

The researchers plan to apply a similar analysis to other traits in blood clotting, says Dr. Karl Desch, assistant professor in the pediatrics department at the U-M Medical School and first author of the study.

"Using the sibling structure in this study, we will hopefully discover more novel loci that determine the variation in these other traits," he said.


'/>"/>

Contact: Jim Erickson
ericksn@umich.edu
734-647-1842
University of Michigan
Source:Eurekalert

Related medicine news :

1. Not Fair! How Sibling Fights May Lead to Later Mood Problems
2. Sibling squabbles can lead to depression, anxiety
3. Developmental Woes Common in Siblings of Children With Autism
4. Study of half siblings provides genetic clues to autism
5. Brief class on easy-to-miss precancerous polyps ups detection, Mayo study shows
6. Study finds flame retardant pollutants at far-flung locations
7. Recession Drove Down Doctor Visits, Study Says
8. Black and Hispanic patients less likely to complete substance abuse treatment, Penn study shows
9. People with diabetes in Ontario getting fewer government-funded eye exams, new study finds
10. Menopause Can Bring Lapses in Memory, Thinking, Study Finds
11. Meds May Spur Compulsive Behaviors in Some Parkinsons Patients: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and the Affordable Care Act. Dr. Botelho advocates for the mass media launching ... movement gives people ongoing opportunities to share their unfortunate experiences; such a movement ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Little Rock, has initiated a charity ... According to the National Foundation to End Senior Hunger, Arkansas ranks first in ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coppin Insurance Agency, an insurance ... in and around the Cape Coral area, is embarking on a charity drive with ... Southwest Florida. , The Harry Chapin Food Bank of Southwest Florida works to provide ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Mederi Therapeutics Inc . hat die behördliche Zulassung durch die ... Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during the ... at Wuhan Union Hospital ...
(Date:12/8/2016)... , December 8, 2016 According to ... Injection Pens Market is expected to be worth US$9.7 ... bn in 2015. Between the forecast years of 2016 and ... CAGR of 7.9%. The leading players operating in the global ... and Company, AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency ...
(Date:12/8/2016)...  Avelas Biosciences, Inc., a clinical stage oncology-focused ... diagnosis through treatment, today presented clinical trial data ... in breast cancer patients utilizing investigational drug product ... Jonathan Unkart , M.D., resident physician at ... delivered the presentation titled "Intraoperative tumor detection using ...
Breaking Medicine Technology: